Connect your AI

Upstream Bio, Inc. UPB Total Equity

Total Equity at other companies

AmgenAMGN

$9.19B+48.1%

Regeneron PharmaceuticalsREGN

$31.42B+6.9%

Aclaris TherapeuticsACRS

$143.65M-0.3%

Shattuck Labs, Inc.STTK

$95.84M+41.8%

SavaraSVRA

$176.04M+19.1%

AnaptysBio, Inc.ANAB

$12.75M-62.5%

Other financials

Income statement

Revenue$1.0M+82.7%

Operating income-$43.6M-36.2%

Net income-$40.6M-48.8%

EPS (diluted)-$0.75-47.1%

Balance sheet

Cash & equivalents$96.7M+35.6%

Total debt$1.1M-34.5%

Total assets$318.1M-30.3%

Cash flow

Operating cash flow-$47.9M-16.2%

CapEx$54.0K-70.8%

Free cash flow-$30.7M-55.0%

Valuation

Market cap$346.11M-40.9%

Enterprise value$250.5M-51.4%

P/S104.2×-151×

Profitability

Operating margin-5,176.5%+1,764pp

Net margin-4,719%+2,752pp

Returns & leverage

Return on equity-41.8%—

Debt / equity0×0.0×

Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Upstream Bio, Inc.'s total equity?: Upstream Bio, Inc. (UPB) reported total equity of $304M in Q1 2026.
How has Upstream Bio, Inc.'s total equity changed year-over-year?: Upstream Bio, Inc.'s total equity decreased by 31.8% year-over-year, from $445.61M to $304M.
What is the long-term trend for Upstream Bio, Inc.'s total equity?: Over 3 years (2022 to 2025), Upstream Bio, Inc.'s total equity has grown at a 47.4% compound annual growth rate (CAGR), from -$106.16M to $339.77M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.